Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-08-14
2007-08-14
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S048000, C514S051000
Reexamination Certificate
active
10290213
ABSTRACT:
The present invention provides a method of preventing or treating an inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases, and sarcoidosis. The method comprises administrating to a subject a pharmaceutical formulation comprising a nucleotide receptor agonist, such as nucleoside diphosphate, nucleoside triphosphate, or dinucleoside polyphosphate, according to general formula Ia, Ib, IIa, IIb, or III. Preferred indications of the present invention are perennial allergic rhinitis, seasonal allergic rhinitis, infectious allergic rhinitis, and allergic conjunctivitis.
REFERENCES:
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5628984 (1997-05-01), Boucher, Jr.
patent: 5635160 (1997-06-01), Stutts, III et al.
patent: 5656256 (1997-08-01), Boucher et al.
patent: 5763447 (1998-06-01), Jacobus et al.
patent: 5789391 (1998-08-01), Jacobus et al.
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 5900407 (1999-05-01), Yerxa et al.
patent: 5902567 (1999-05-01), Boucher, Jr.
patent: 5935555 (1999-08-01), Stutts, III et al.
patent: 5958897 (1999-09-01), Jacobus et al.
patent: 5968913 (1999-10-01), LaCroix et al.
patent: 5972904 (1999-10-01), Jacobus et al.
patent: 5981506 (1999-11-01), Jacobus et al.
patent: 6022527 (2000-02-01), Boucher, Jr. et al.
patent: 6133247 (2000-10-01), Boucher, Jr.
patent: 6143279 (2000-11-01), Boucher, Jr. et al.
patent: 6147056 (2000-11-01), Gilchrest et al.
patent: 6159952 (2000-12-01), Shaffer et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6610274 (2003-08-01), Gardner
patent: 6977246 (2005-12-01), Pendergast et al.
patent: 2001/0026926 (2001-10-01), Klein et al.
patent: 2004/0241149 (2004-12-01), De Simone
patent: WO94/08593 (1994-04-01), None
patent: WO96/40059 (1996-12-01), None
patent: WO97/05195 (1997-02-01), None
patent: WO97/29756 (1997-08-01), None
patent: WO97/35591 (1997-10-01), None
patent: WO98/03177 (1998-01-01), None
patent: WO98/15835 (1998-04-01), None
patent: WO98/03182 (1998-05-01), None
patent: WO98/19685 (1998-05-01), None
patent: WO98/34593 (1998-08-01), None
patent: WO 9834942 (1998-08-01), None
patent: WO99/09998 (1999-03-01), None
patent: WO 9909998 (1999-03-01), None
patent: WO99/32085 (1999-09-01), None
patent: WO99/61012 (1999-12-01), None
patent: WO98/34942 (2000-01-01), None
patent: WO00/30629 (2000-06-01), None
patent: WO00/50024 (2000-08-01), None
Cury et al. Clinical Pharmacology of Agents Used in the Contemporary Management of Asthma. Jacksonville Medicine. Aug. 1998.
Grrenberg et al. cAMP and Purinergic P2y Receptors Upragulate and Enhance Inducible NO Synthase mRNA and Protein in vivo. Am J Physiol Lung Cell Mol Physiol 273 (5): 967.
Elgert, Klaus. Immunology. Wiley-Liss 1996. pp. 291-305.
Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill Medical Publishing Division, 2001, pp. 54-56.
Brown, et al., “Evidence that UTP & ATP Regulate Phospholipase C through a Common Extracellular 5′-Nucleotide Receptor In Human Airway Epithelial Cells,”Mol. Pharmacol. 40, 648-655 (1991).
Dichmann, et al., “Adenosine triphosphate-induced oxygen radical production and CD11b up-regulation: Ca++ mobilization and actin reorganization in human eosinophils,”Blood95(3): 973-8 (2000).
Ferrari, et al., “P2 purinergic receptors of human eosinophils: characterization and coupling to oxygen radical production,”FEBS Lett. 486(3):217-24 (2000).
Izushi et al., “Essential Role of ATP and Possibility of Activation of Protein Kinase C in Ca2+—Dependent Histamine Release from Permeabilized Rat Peritoneal Mast Cells,”Pharmacology42(6): 297-308 (1991).
Jaffar et al., “Histamine secretion from mast cells stimulated with ATP,”Agents Actions30(1-2): 64-6 (1990).
Kannan, “Neutrophil degranulation: coactivation of chemokine receptor(s) is required for extracellular nucleotide-induced neutrophil degranulation,”Med. Hypotheses57(3): 306-9 (2001).
McCloskey, et al., “Chemotaxis of Rat Mast Cells Toward Adenine Nucleotides,”J. Immunol. 163(2): 970-7 (1999).
Merritt et al., “Human Neutrophils Have a Novel Purinergic P2-type Receptor Linked to Calcium Mobilization,”Cell Signal3(3): 243-9 (1991).
Mohanty, et al., “Effects of purine and pyrimidine nucleotides on intracellular Ca2+ in human eosinophils: Activation of purinergic P2Y receptors,”J. Allergy Clin. Immunol. 107(5): 849-55 (2001).
Katzung,Basic and Clinical Pharmacology431 (1989).
Saito, et al., “Extracellular ATP Stimulates Interleukin-Dependent Cultured Mast Cells and Eosinophils through Calcium Mobilization,”Int. Arch. Allergy Appl. Immunol. 94(1-4): 68-70 (1991).
Schulman, et al., “ATP Modulates Anti-IgE-Induced Release of Histamine from Human Lung Mast Cells,”Am. J. Respir. Cell. Mol. Biol. 20(3): 530-7 (1999).
Walker, et al., “Nucleotide Responses of Human Neutrophils,”Lab Invest. 64(1): 105-12 (1991).
Yerxa, et al., “P2Y2receptor agonists: structure, activity and therapeutic utility,”Drugs of the Future24(7): 759-769 (1999).
http://www.graylab.ac.uk/cgi.bin/omd?query=allegy, Oct. 19, 2001.
http://www.medterms.com/script/main/ad/asp?articlekey=3979, Oct. 23, 2001.
International Search Report dated Feb. 20, 2003.
Greenberg, et al., “cAMP and purinergic P2y receptors upregulate and enhance inducible NO synthase mRNA and protein in vivo,” The American Physiological Society pp. L967-L977, 1997.
Loredo & Benton, “ATP and UTP Activate Calcium-Mobilizing P2u-like Receptors and Act Synergistically with Interleukin-1 to Stimulate Prostaglandin E2Release from Human Rheumatoid Synovial Cells,”Arthritis&Rheumatism41:2 pp. 246-255 (1998).
Peterson Ward M.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Kung Viola T.
McIntosh Traviss
LandOfFree
Method for treating or preventing inflammatory diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating or preventing inflammatory diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating or preventing inflammatory diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861819